PHASE II TRIPHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMAAL OF RESPONSE-ADAPTED THERAPY BASED ON POSITRON EMISSION TOMOGRAPHY (PET) FOR BULKY STAGE I AND STAGE II CLASSICAL HODGKIN LYMPHOMA (HL) An Alliance trial conducted by CALGB and open only to CALGB, ACOSOG and NCCTG - Regional Cancer Care Associates LLC

Clinical Trials

PHASE II TRIPHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMAAL OF RESPONSE-ADAPTED THERAPY BASED ON POSITRON EMISSION TOMOGRAPHY (PET) FOR BULKY STAGE I AND STAGE II CLASSICAL HODGKIN LYMPHOMA (HL) An Alliance trial conducted by CALGB and open only to CALGB, ACOSOG and NCCTG

Type of Cancer
Lymphoma
Locations
Hackensack
Sponsor
Celgene
Protocol Number
CC-122-CLL-001
Cancer Diagnosis
To Learn More Call
201-510-0910